Analyst Price Target is $343.83
▲ +65.03% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Madrigal Pharmaceuticals in the last 3 months. The average price target is $343.83, with a high forecast of $410.00 and a low forecast of $150.00. The average price target represents a 65.03% upside from the last price of $208.35.
Current Consensus is
Moderate Buy
The current consensus among 13 contributing investment analysts is to moderate buy stock in Madrigal Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Read More